The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome

Απλή σελίδα τεκμηρίου
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorGazi, I. F.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorAthyros, V. G.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorKiortsis, D. N.en
dc.date.accessioned2015-11-24T19:41:53Z
dc.date.available2015-11-24T19:41:53Z
dc.identifier.issn0021-9150-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24553
dc.rightsDefault Licence-
dc.subject1-Alkyl-2-acetylglycerophosphocholine Esterase/*blooden
dc.subjectAdulten
dc.subjectAnti-Obesity Agents/pharmacology/therapeutic useen
dc.subjectCardiovascular Diseases/drug therapy/etiologyen
dc.subjectCholesterol, LDL/*blooden
dc.subjectDrug Therapy, Combinationen
dc.subjectFemaleen
dc.subjectFenofibrate/pharmacology/*therapeutic useen
dc.subjectHumansen
dc.subjectHypolipidemic Agents/pharmacology/therapeutic useen
dc.subjectLactones/pharmacology/*therapeutic useen
dc.subjectMaleen
dc.subjectMetabolic Syndrome X/drug therapy/etiologyen
dc.subjectMiddle Ageden
dc.subjectObesity/complications/*drug therapyen
dc.subjectOverweighten
dc.subjectPhospholipases A2en
dc.subjectRisk Factorsen
dc.titleThe effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndromeen
heal.abstractBACKGROUND: Increased concentration of small dense LDL cholesterol (sdLDL-C) and activity of lipoprotein-associated phospholipase A2 (Lp-PLA(2)) are considered as emerging cardiovascular risk factors and are commonly encountered in subjects with metabolic syndrome (MetS). OBJECTIVE: The primary endpoint of this study was the effect of orlistat and fenofibrate, alone or in combination, on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients (body mass index>28 kg/m(2)) with MetS. METHODS: Patients (n=89) were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg three times daily (O group), micronized fenofibrate 200mg/day (F group) or both (OF group) for 6 months. RESULTS: Significant reductions of sdLDL-C levels were observed in all treatment groups. Groups F and OF experienced a greater reduction in sdLDL-C levels (p<0.05) together with a greater increase in LDL particle diameter (p<0.05) compared with group O. Total plasma Lp-PLA(2) activity significantly decreased in all treatment groups. The reduction of Lp-PLA(2) was more pronounced with OF administration compared with each monotherapy (p<0.05). CONCLUSION: Orlistat and fenofibrate exhibited favorable effects on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients with MetS. Importantly, combination treatment had a more favorable effect on these risk factors.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.atherosclerosis.2006.07.010-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16911813-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0021915006004084/1-s2.0-S0021915006004084-main.pdf?_tid=d29956a44a96251d298a203a6bbb2079&acdnat=1333531139_a7897d9d8d05921b4cdc9ffe783e74bc-
heal.journalNameAtherosclerosisen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2007-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ